Insulin Out-of-Stock; Yet Another GLP/GIP Agonist; Digital Diabetes Tools Worth It?
(MedPage Today) -- Both generic and branded formulations of 10-mL vials of insulin lispro injection (Humalog) will be temporarily out of stock through the start of April, Eli Lilly announced.
A new study predicted global fertility, which has been... (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - March 26, 2024 Category: Endocrinology Source Type: news
Eli Lilly Reports Temporary Shortage of Humalog and Insulin Lispro Injection
MONDAY, March 25, 2024 -- Eli Lilly& Co. announced on Friday a temporary shortage of two of its insulin products. " The 10 mL vials of Humalog and Insulin Lispro Injection are or will be temporarily out of stock at wholesalers and some... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 25, 2024 Category: Pharmaceuticals Source Type: news
Eli Lilly Warns That 2 Insulin Products Will Be in Short Supply
MONDAY, March 25, 2024 -- Drugmaker Eli Lilly& Co is announcing a temporary shortage of two of its insulin products. " The 10 mL [millilter] vials of Humalog® and Insulin Lispro Injection are or will be temporarily out of stock at... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - March 25, 2024 Category: General Medicine Source Type: news
Weight loss from Lilly's Zepbound reversed after stopping treatment, study shows
[1/2] Lilly Biotechnology Center is shown in San Diego, California, U.S. March 1, 2023 after Eli Lilly and Co on Wednesday said it will cut list prices by 70% for its most commonly prescribed insulin products, Humalog and Humulin, beginning from the fourth quarter of this year. REUTERS/Mike…#sandiego #elililly #humulin #mikeblakefile #jama #lilly #zepbound #novonordisk #cowegovyandozempic #glp1 (Source: Reuters: Health)
Source: Reuters: Health - December 12, 2023 Category: Consumer Health News Source Type: news
Reductions Seen in HbA1c, Body Weight With Once-Weekly Tirzepatide
FRIDAY, Oct. 6, 2023 -- For patients with inadequately controlled type 2 diabetes, once-weekly subcutaneous injections of tirzepatide yield reductions in hemoglobin A1c (HbA1c) and body weight compared with insulin lispro, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 6, 2023 Category: Pharmaceuticals Source Type: news
Adding Tirzepatide to Basal Insulin Cuts HbA1c in Poorly Controlled T2D
(MedPage Today) -- HAMBURG, Germany -- Adding weekly tirzepatide (Mounjaro) to basal insulin reduced HbA1c in patients with poorly controlled type 2 diabetes compared with adding three-times-daily insulin lispro, the phase IIIb SURPASS-6 trial... (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 3, 2023 Category: Cardiology Source Type: news
Tirzepatide With Insulin Glargine Improves Type 2 Diabetes Tirzepatide With Insulin Glargine Improves Type 2 Diabetes
Adding tirzepatide to insulin glargine leads to greater improvements in A1c, body weight, and less hypoglycemia compared with prandial insulin lispro show data simultaneously published in JAMA.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - October 3, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Sanofi Is Now the Third Insulin Producer to Slash Prices
Sanofi will cut the U.S. list price of two of its insulins, making it the third major producer of the diabetes medicine to recently slash prices.
French pharmaceutical maker Sanofi will reduce the U.S. list price of Lantus, its most-prescribed insulin, by 78%, according to a statement Thursday. The company will also reduce the list price of Apidra by 70%.
“We are pleased to see others join our efforts to help patients as we now accelerate the transformation of the U.S. insulin market,” said Olivier Bogillot, the head of U.S. general medicines. “Our decision to cut the list price of our lead insulin needs ...
Source: TIME: Health - March 17, 2023 Category: Consumer Health News Authors: Ilena Peng/Bloomberg Tags: Uncategorized bloomberg wire Drugs healthscienceclimate Source Type: news
Insulin costs: Novo Nordisk to lower list price for insulin products, following similar move by Eli Lilly
Novo Nordisk will lower the U.S. list price of some of its insulin products by up to 75%, the Danish drugmaker said Tuesday. The change — which will take effect on Jan. 1, 2024 — follows a similar move by Eli Lilly, which said this month that it will lower the list price for several of its…#novonordisk #danish #elililly #humalog #followingelilillys #larrylevitt #kff #staciedusetzina #nashville #tennessee (Source: Reuters: Health)
Source: Reuters: Health - March 14, 2023 Category: Consumer Health News Source Type: news
Novo Nordisk Plans Price Cuts for Several Insulins
Novo Nordisk will start slashing some U.S. insulin prices up to 75% next year, following a path set earlier this month by rival Eli Lilly.
The Danish drugmaker said Tuesday that pre-filled pens and vials of long-acting and short-acting insulins will see price reductions. They include Levemir, Novolin, NovoLog and NovoLog Mix70/30.
Novo also will drop the list price of some unbranded products to match the lower price of the branded insulins.
The price cuts go into effect Jan. 1.
Eli Lilly and Co. said March 2 that it will cut the list prices for its most commonly prescribed insulin, Humalog, and for another insulin, Humulin...
Source: TIME: Health - March 14, 2023 Category: Consumer Health News Authors: Associated Press Tags: Uncategorized Drugs healthscienceclimate wire Source Type: news
Eli Lilly ’s Price Cut Is Gamechanging. But Insulin Isn’t the Only High Cost for People With Diabetes
Early each year, Kristin Thompson-Lerberg sits down with her husband to plan how they’ll reach their family’s insurance policy’s $3,000 deductible. The conversation is always short: Thompson-Lerberg needs about 8 vials of insulin each month to treat her Type-1 diabetes, and at $275 per vial before insurance kicks in, it takes just two months to reach the deductible from insulin alone.
But their budget expanded after pharmaceutical giant Eli Lilly announced on Mar. 1 that the monthly out-of-pocket prices of their insulin brands will soon be capped at $35 regardless of a person’s insurance. For Humalo...
Source: TIME: Health - March 7, 2023 Category: Consumer Health News Authors: Haley Weiss Tags: Uncategorized Health Care healthscienceclimate Source Type: news
Eli Lilly ’s Price Cut Is Game-changing. But Insulin Isn’t the Only High Cost for People With Diabetes
Early each year, Kristin Thompson-Lerberg sits down with her husband to plan how they’ll reach their family’s insurance policy’s $3,000 deductible. The conversation is always short: Thompson-Lerberg needs about 8 vials of insulin each month to treat her Type-1 diabetes, and at $275 per vial before insurance kicks in, it takes just two months to reach the deductible from insulin alone.
But their budget expanded after pharmaceutical giant Eli Lilly announced on Mar. 1 that the monthly out-of-pocket prices of their insulin brands will soon be capped at $35 regardless of a person’s insurance. For Humalo...
Source: TIME: Health - March 7, 2023 Category: Consumer Health News Authors: Haley Weiss Tags: Uncategorized Health Care healthscienceclimate Source Type: news
Here ’s How the Other Major Insulin Makers Are Responding After Eli Lilly’s Price Cap
Facing pressure to curb diabetes-treatment costs, Eli Lilly & Co. announced on March 1 that it is slashing insulin prices and immediately capping the out-of-pocket cost of all of its insulins at $35 a month. President Joe Biden, who made insulin costs a focus of his State of the Union speech last month, praised the move by Lilly and called on other drugmakers to also lower insulin prices.
The price cuts by the Indianapolis-based Lilly, one of the world’s top three insulin producers, are expected to provide critical relief to the millions of Americans who rely on the medicine to control their blood sugar levels. S...
Source: TIME: Health - March 2, 2023 Category: Consumer Health News Authors: Nik Popli Tags: Uncategorized Drugs News Team Source Type: news
By Capping Out-Of-Pocket Price, Eli Lilly Could Transform Insulin Market
In what could represent a significant transformation of the insulin marketplace, Eli Lilly has announced it will slash the price of two of its insulin products by 70%; Humalog and Humulin. And, the company will cap commercially insured and uninsured patients ’ out-of-pocket costs at $35 per month. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 1, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation Business /business Editors' Pick editors-pick pharma & Source Type: news
Eli Lilly To Lower Insulin Prices And Introduce A $35 Out-Of-Pocket Monthly Cap For Commercially Insured And Uninsured Diabetics
In what could represent a significant transformation of the insulin marketplace, Eli Lilly has announced it will slash the price of two of its insulin products by 70%; Humalog and Humulin. And, the company will cap commercially insured and uninsured patients ’ out-of-pocket costs at $35 per month. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - March 1, 2023 Category: Pharmaceuticals Authors: Joshua Cohen, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & Source Type: news
